HC Wainwright Reiterates "Buy" Rating for Palvella Therapeutics (NASDAQ:PVLA)

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $38.00 price target on the stock. HC Wainwright's target price would indicate a potential upside of 55.36% from the company's previous close.

A number of other research firms also recently commented on PVLA. TD Cowen started coverage on Palvella Therapeutics in a report on Wednesday, February 5th. They issued a "buy" rating and a $44.00 price objective on the stock. Chardan Capital assumed coverage on Palvella Therapeutics in a research note on Wednesday, April 9th. They issued a "buy" rating and a $50.00 price objective on the stock. Jones Trading began coverage on Palvella Therapeutics in a research report on Tuesday, March 25th. They set a "buy" rating and a $45.00 target price for the company. Scotiabank initiated coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Palvella Therapeutics in a report on Wednesday, March 26th. They set a "buy" rating and a $45.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $44.43.

Palvella Therapeutics Trading Up 1.5 %

PVLA traded up $0.37 on Wednesday, reaching $24.46. 51,579 shares of the company traded hands, compared to its average volume of 71,726. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $29.27. The stock has a market cap of $269.52 million, a P/E ratio of -2.02 and a beta of 0.10. The business has a 50 day moving average price of $24.56.

Insider Buying and Selling

In other Palvella Therapeutics news, Director George M. Jenkins purchased 2,500 shares of the stock in a transaction on Wednesday, April 9th. The shares were purchased at an average price of $20.13 per share, with a total value of $50,325.00. Following the acquisition, the director now directly owns 183,171 shares of the company's stock, valued at $3,687,232.23. This represents a 1.38 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 6.39% of the stock is owned by company insiders.

Institutional Trading of Palvella Therapeutics

Several institutional investors have recently made changes to their positions in the business. BML Capital Management LLC bought a new position in Palvella Therapeutics during the fourth quarter worth about $506,000. Nantahala Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter worth approximately $3,001,000. Blue Owl Capital Holdings LP acquired a new stake in Palvella Therapeutics in the 4th quarter valued at $3,001,000. Adams Street Partners LLC acquired a new stake in Palvella Therapeutics in the 4th quarter valued at $4,916,000. Finally, Samsara BioCapital LLC acquired a new position in Palvella Therapeutics during the fourth quarter worth $8,154,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.